SAINT™ (Stanford Accelerated Intelligent Neuromodulation Therapy) is now approved to treat depression and was awarded "breakthrough device" designation by the U.S. FDA.

How It Works: TMS acts through neuroplasticity, the principle that the brain's circuitry can change with the right sort of encouragement, namely, magnetic pulses that are patterned in customized way to strengthen the connections for you.

How does SAINT differ from conventional TMS?: Key differences include

How can I get SAINT Treatment?: LATMS is the only center in Los Angeles that is authorized to provide the genuine SAINT protocol as reviewed by the FDA; others may try to imitate it, but in Los Angeles, only LATMS is permitted to use the patent-protected algorithms.
 
        •     Email us at saint@LATMS.com
        •     Call us at 310-455-6210
        •     We require a referral by your current treating physician

Is SAINT experimental? No, SAINT received its FDA clearance in 2022, and we perform treatments using the SAINT protocol as a clinical service; because it is very new, most insurance companies do not include it in their list of "covered benefits" and so patients are required to pay out-of-pocket.

We are performing a research study in conjunction with the clinical treatments, in which individuals are closely monitored during treatment and afterwards. This project is the first time that SAINT is being studied outside of academic research centers, so we look forward to measuring successes outside of the "ivory tower."

Who is LATMS? LATMS is Southern California's premier program for treatment resistant depression and other psychiatric conditions. It was founded in 2018 by Ian Cook, MD DLFAPA FCTMSS, a graduate of Princeton University, the Yale School of Medicine, and residency and fellowship programs at UCLA's Neuropsychiatric Institute and Hospital. He has been board certified since 1996.

A leader in the field of neuromodulation, Dr. Cook founded the TMS program at UCLA in 2009 and was the first psychiatrist to provide TMS treatment at any of the University of California medical centers. He has been a Board Member of the Clinical TMS Society (CTMSS) since 2013 and is the inaugural Vice President of the Foundation for the Advancement of Clinical TMS (FACTMS). An innovator and researcher, he has been awarded two dozen U.S. Patents for biomedical technologies and is an author on over 150 scientific publications. Before leaving UCLA, he held an endowed chair in depression research. As a Professor Emeritus of Psychiatry and of Bioengineering, Dr. Cook continues to contribute to scientific research as a consultant to professors at USC and Stanford University on NIH-funded grants. His contributions to the field were recognized when we was awarded the President's Award by CTMSS in 2021.